Clinical trials: Elderly Infection
Influenza, Human
A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in…
- Trial name
- NCT05446740
- Testing
- GSK4382276A Dose level 1, GSK4382276A Dose level 2, GSK4382276A Dose level 3
- Where
- 7 sites in Belgium, Canada and 1 more
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue Fever, Dengue Hemorrhagic Fever
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
The aim of the study was to evaluate the safety and immunogenicity of the Dengue vaccine in a population of special interest, such as HIV-positive adults previously exposed to dengue.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Immunodeficiency Virus
- Trial name
- NCT02741128
- Testing
- CYD Dengue Vaccine
- Where
- 4 sites in Brazil
- Volunteers
- 133 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in…
- Trial name
- NCT04732871
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 46 sites in United States, Finland and 3 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Latent Tuberculosis Infection (LTBI)
C-TST for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Indonesia
This is an operational research in household/close contacts of confirmed TB patients to evaluate the effectiveness of C-TST compared to IGRA test in identifying latent TB cases using parameters of effectiveness and safety.
- Trial name
- C-TST (NCT07587164)
- Testing
- Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST)
- Where
- Indonesia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Varicella (Chickenpox)
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines.
- Trial name
- NCT07415252
- Testing
- NBP608 (Mid Potency), NBP608 (Low Potency), Varivax®
- Where
- 14 sites in Honduras, Philippines and 2 more
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the GSK Biologicals' pneumococcal vaccine 2830930A in toddlers aged 12 to 23 months at study entry.
- Trial name
- NCT01485406
- Testing
- Pneumococcal vaccine GSK2830930A, Synflorix™
- Where
- 4 sites in Germany
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis A, Hepatitis A Virus
Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents
The aim of this study is to describe the safety profile of Avaxim 80U Pediatric, in order to confirm the good safety profile of the vaccine.
- Trial name
- NCT02011763
- Testing
- Avaxim 80U Pediatric: Inactivated Hepatitis A Virus
- Where
- China
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid19
Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10^6 PFU and 10^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and…
- Trial name
- CVXGA1-001 (NCT04954287)
- Testing
- CVXGA1 low dose, CVXGA1 high dose
- Where
- 4 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
Rabies
Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)
The Phase 3 clinical trial of freeze-dried human rabies vaccine (human diploid cells) adopted a randomized, blinded, parallel control,non-inferiority design,and administered vaccines to participants aged 10 to 60 years with…
- Trial name
- NCT07028801
- Testing
- Freeze-dried human rabies vaccine (human diploid cells)
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Influenza Vaccines
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00586469
- Testing
- Fluviral
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study…
- Trial name
- NCT00500266
- Testing
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
- Where
- 59 sites in United States, Germany and 1 more
- Volunteers
- 1,053 people, healthy volunteers welcome
- Sponsor
- Pfizer
Human Immunodeficiency Virus (HIV)
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children
The purpose of the study is to assess the ability to swallow the Darunavir/Cobicistat (DRV/COBI) fixed dosed combination (FDC) tablet dispersed in water.
- Trial name
- NCT05197075
- Testing
- DRV/COBI FDC
- Where
- 6 sites in United States, South Africa and 1 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Influenza, Human
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
Elderly healthy subjects will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
- Trial name
- NCT03657719
- Testing
- GC3114, GCFLU Quadrivalent
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Dysentery, Shigellosis
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in infants and children aged from 6 months to 5 years.
- Trial name
- NCT05156528
- Testing
- S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine
- Where
- 9 sites in China
- Volunteers
- 21,000 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Respiratory Syncytial Virus Infection
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the safety and immunogenicity of the the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in adults aged 18 years and older.
- Trial name
- NCT06904222
- Testing
- Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China
The purpose of this clinical study, CLO-SCB-2019-010, is to assess the immunogenicity, reactogenicity and safety of the SCB-2019 vaccine in Chinese participants, and to show the comparability of the immune response versus…
- Trial name
- NCT04954131
- Testing
- Candidate Vaccine, SCB-2019
- Where
- 2 sites in China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Zhejiang Clover Biopharmaceuticals, Inc.
Hand, Foot and Mouth Disease
Active Case Finding of Clinical Hand Foot Mouth Disease in Children Aged 6 Months Old to 18 Years Old in Indonesia
An observational study of active case surveillance to identify the pathogens of clinically diagnosed HFMD cases aged 6 months to 18 years old recruited from puskesmas and hospitals in Indonesia.
- Trial name
- NCT06251219
- Testing
- PCR
- Volunteers
- 100 people
- Sponsor
- Sinovac Biotech Co., Ltd
Gram-positive Bacterial Infections
Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics
The purpose of this study is to evaluate the pharmacokinetics of a single dose of daptomycin in patients aged 2-17 years old who have a suspected or proven gram-positive infection for which they are receiving standard antibiotic…
- Trial name
- NCT00136292
- Testing
- daptomycin
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacterial Infections
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.
- Trial name
- NCT02527681
- Testing
- Ceftobiprole medocaril
- Where
- 14 sites in United States, Belgium and 4 more
- Volunteers
- 15 people
- Sponsor
- Basilea Pharmaceutica
Influenza
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups
The purpose of this study is to assess the safety and tolerability of, and the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult and elderly population and in specified risk groups.
- Trial name
- NCT00711295
- Testing
- H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
- Where
- 45 sites in Austria, Belgium and 5 more
- Volunteers
- 3,583 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.